A leading provider of
innovative DNA Screening solutions
BCR/ABL Translocation Dual Fusion LPH007
The presence of the Philadelphia chromosome, produced as a result of the Philadelphia translocation t(9;22)(q34;q11), has important diagnostic and prognostic implications in a number of Haematological disorders. The abnormality is characteristic of CML (found in around 90% of cases) but represents a significant abnormality in 30% of adult and 2 to 10% of childhood ALL cases. This rearrangement is also seen in rare cases of AML. The stereotypic translocation fuses the ABL proto-oncogene to the BCR gene, giving rise to the BCR/ABL fusion gene, which is an active Tyrosine Kinase.
BCR/ABL Translocation Dual Fusion Probes
Cat. No. LPH 007-S (5 tests)
Cat. No. LPH 007 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK